Oxford University and London, UK-based private equity and venture capital firm Kingsley Capital Partners have launched a new research program to investigate the role of cannabinoids in biology and medicine.
The program aims to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.
Through an initial investment of up to £10m provided by Kingsley, funded through its new portfolio company Oxford Cannabinoid Technologies (OCT), and a series of research projects performed by medical research teams, Oxford will seek to identify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.
The research program will develop the results into innovative therapies. Over time, OCT will fund additional cannabinoid programs with the University across different therapeutic areas.